Interferon Alfa-2b (International)
In the US, Interferon Alfa-2b (interferon alfa-2b systemic) is a member of the drug class antineoplastic interferons and is used to treat Angioblastoma, Condylomata Acuminata, Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Follicular Lymphoma, Hairy Cell Leukemia, Hepatitis B, Hepatitis C, Immune Thrombocytopenia, Kaposi's Sarcoma and Melanoma.
US matches:
Scheme
USAN
ATC (Anatomical Therapeutic Chemical Classification)
L03AB05,S01AD05
CAS registry number (Chemical Abstracts Service)
0099210-65-8
Chemical Formula
C860-H1353-N229-O255-S9
Molecular Weight
19269
Therapeutic Categories
Antineoplastic agent
Antiviral agent: Treatment of hepatitis
Biological response modifier, BRM
Immunomodulator
Foreign Names
- Interferonum alfa-2b (Arg-23; His-34) (Latin)
- Interferon alfa-2b (Arg-23; His-34) (German)
- Interféron alfa-2b (Arg-23; His-34) (French)
- Interferón alfa-2b (Arg-23; His-34) (Spanish)
Generic Names
- Interferon Alfa-2b (OS: USAN, BAN)
- Interferon Alfa-2b (Genetical Recombination) (OS: JAN)
- IFNalpha2b (IS)
- r-IFN-Alfa-2b (IS)
- Sch 30500 (IS)
- Interferon Alfa-2 Concentrated Solution (PH: BP 2016)
- Interferon Alfa-2b (Genetical Recombination) (PH: JP XVI)
Brand Names
- Alfaferone
Alfa Wassermann, Lebanon - Allergoferon [+ Loratadine]
Firn M, Russian Federation - Allergoferon Beta [+ Betamethasone]
Firn M, Russian Federation - Alphaferoi
Akber Brothers, Pakistan - An Da Fen
Anke Biotechnology Group, China - An Fu Long
HuaLiDa Biotechnology, China - An Te Fu
Neptunus Pharmaceutical, China - Anferon
Atco, Pakistan - Bioferon
Bio Sidus, Thailand; Sidus, Argentina; Sidus, Paraguay; Sidus, Uruguay; Instituto Sidus, Lebanon - Blauferon-B
Pharmatec, Pakistan - Blauferon-B 3 MUI
Blausiegel, Uruguay - Cell-aid
Werrick, Pakistan - Ceron-alfa
Biocare, Pakistan - Chang Sheng De Jia
Changchun Institute of Biological Products, China - Chang Sheng Fu Kang
Changchun Institute of Biological Products, China - Enduferon
Heber, Philippines - Genferon [+ Taurine]
ZAO "BIOKAD", Georgia - Green-alpha
Genesis, Pakistan - Heberon-alpha
Macter, Pakistan - Inf 3Mui
Bago, Paraguay - Inrec
Clausen, Uruguay - Intefen
NovaMed, Pakistan - Inter 2B
Biosidus, Argentina - Interferon Alfa 2b Cassara
Promofarma, Uruguay; Varifarma, Argentina - Interferon Alfa 2b V y T Farma
V y T Farma, Paraguay - Interferon Alfa-2b Humano Recombinante Bago
Laboratorio Bago, Chile - Interferonas alfa-2b
Sicor Biotech, Lithuania - Interlong
Hepacare, Pakistan; Neptunus Pharmaceutical, China - Intron A
Bayer Schering, Iran; M.S.D., Portugal; Merck Canada, Canada; Merck Sharp & Dohme, Australia; Merck Sharp & Dohme, Bosnia & Herzegowina; Merck Sharp & Dohme, Hong Kong; Merck Sharp & Dohme, Croatia (Hrvatska); Merck Sharp & Dohme, Mexico; Merck Sharp & Dohme, New Zealand; Merck Sharp & Dohme, Poland; Merck Sharp & Dohme, Romania; Merck Sharp & Dohme, Slovenia; MSD, Japan; MSD Belgium, Belgium; MSD Belgium, Luxembourg; MSD Merck Sharp & Dohme, Germany; Schering, United Arab Emirates; Schering, Egypt; Schering, Iraq; Schering, Jordan; Schering, Qatar; Schering, Saudi Arabia; Schering, United States; Schering, Yemen; Schering-Plough, Bahrain; Schering-Plough, Indonesia; Schering-Plough, Israel; Schering-Plough, Kuwait; Schering-Plough, Lebanon; Schering-Plough, Philippines; Schering-Plough, Serbia; Schering-Plough, Russian Federation; Schering-Plough, Syria; Schering-Plough, Venezuela; Schering-Plough, South Africa; Schering-Plough Labo, Macedonia - Intron A (Merck Sharp & Dohme
China MSD, China - Intron A
Merck Sharp & Dohme Pharma Singapore, Singapore - Intron A 10 Mio IE
MSD, Switzerland - Intron A 30 Mio IE
MSD, Switzerland - Intron A 60 Mio IE
MSD, Switzerland - Intron A Multi-Dose
Schering-Plough, Taiwan - Intron A Redipen
Merck Sharp & Dohme, Australia - Intron Redipen
Schering-Plough, Venezuela - IntronA
Merck, Iceland; Merck Sharp & Dohme, Chile; Merck Sharp & Dohme, United Kingdom; Merck Sharp & Dohme, Greece; Merck Sharp & Dohme, Lithuania; MSD, Czech Republic; MSD, Denmark; MSD, Finland; MSD, Ireland; MSD, Norway; MSD, Sweden; MSD, Slovakia; Schering-Plough, Italy; Schering-Plough, Lithuania - Introna
Merck Sharp & Dohme, Cyprus; Merck Sharp & Dohme, Estonia; Merck Sharp & Dohme, Spain - Intron-A
Atco, Pakistan; Merck Sharp & Dohme, Mexico; Merck Sharp & Dohme, Malaysia; MSD Merck Sharp & Dohme, Turkey - IntronA 18 millió NE
MSD Pharma, Hungary - IntronA 18 Mio. I.E.
Merck Sharp & Dohme, Austria - IntronA 18 Mio. I.E./3ml
Merck Sharp & Dohme, Austria - IntronA 25 Mio. I.E./2,5ml
Merck Sharp & Dohme, Austria - IntronA 30 millió NE
MSD Pharma, Hungary - IntronA 30 Mio. I.E.
Merck Sharp & Dohme, Austria - IntronA 60 millió NE
MSD Pharma, Hungary - IntronA 60 Mio. I.E.
Merck Sharp & Dohme, Austria - Jie Fu
HuaLiDa Biotechnology, China - Kaifu
Kawin Technologie, China - Kalferon
Kalbe, Indonesia - Laferon
Rubikon, Georgia - Lai Fu Long
Beisheng Medicine Industry Hansheng Pharmaceutical, China - Li Fen Neng
Hayao Pharmaceutical Group Holding, China - Li Ya Mei
Hayao Pharmaceutical Group Holding, China - Longhuanuo
Binhai Xinbao, China - Ophthalmoferon [+ Diphenhydramine]
ZAO, Georgia - Peg-Intron
Schering-Plough, Oman - Realdiron
Sicor Biotech, Lithuania; Sicor Biotech, Serbia - Rebetron [+ Ribavirin]
Schering-Plough, Kuwait - Refergen
Sicor Biotech, Lithuania - Reliferon
Ambica, Philippines - Ruferon-Rn
Rubikon, Georgia - Urifron
Probiomed, Mexico - Urifrón
Probiomed, Dominican Republic; Probiomed, Guatemala; Probiomed, Honduras; Probiomed, El Salvador - Viferon
Feron, Georgia - Viraferon
Fulford, India; Schering-Plough, Lithuania - Yi Sheng
Kawin Technologie, China - You Ni Long
Tongyong Tongmeng Pharmaceutical, China
Glossary
| Term | Definition |
|---|---|
| BAN | British Approved Name |
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| USAN | United States Adopted Name |
Further information on drug naming conventions: International Nonproprietary Names.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.